Clinical Trial Update: Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating mosunetuzumab for newly diagnosed extranodal marginal zone lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone Lymphoma

Drugs mentioned

• Mosunetuzumab (Lunsumio) (mosunetuzumab)

Snippet

Sponsor: Izidore Lossos, MD | Conditions: Extranodal Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING